These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23789705)

  • 21. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
    Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
    J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
    Eisenberg J; Pepe M; Williams-Warren J; Vasiliev M; Montgomery AB; Smith AL; Ramsey BW
    Chest; 1997 Apr; 111(4):955-62. PubMed ID: 9106575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems.
    Mashat M; Clark BJ; Assi KH; Chrystyn H
    Pulm Pharmacol Ther; 2016 Apr; 37():37-42. PubMed ID: 26747025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition.
    Coates AL; Dinh L; MacNeish CF; Rollin T; Gagnon S; Ho SL; Lands LC
    J Aerosol Med; 2000; 13(3):169-78. PubMed ID: 11066020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients].
    Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ
    Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics.
    Hasan MA; Lange CF
    J Aerosol Med; 2007; 20(3):282-93. PubMed ID: 17894535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study.
    Meerburg JJ; Andrinopoulou ER; Bos AC; Shin H; van Straten M; Hamed K; Mastoridis P; Tiddens HAWM
    J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):61-72. PubMed ID: 32073919
    [No Abstract]   [Full Text] [Related]  

  • 35. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
    Chuchalin A; Amelina E; Bianco F
    Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of aerosolized tobramycin in cystic fibrosis.
    Pai VB; Nahata MC
    Pediatr Pulmonol; 2001 Oct; 32(4):314-27. PubMed ID: 11568993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project.
    Coates AL; Green M; Leung K; Chan J; Ribeiro N; Louca E; Ratjen F; Charron M; Tservistas M; Keller M
    Pediatr Pulmonol; 2008 Aug; 43(8):753-9. PubMed ID: 18613006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of aerosolized antibiotics in cystic fibrosis patients.
    Moss RB
    Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.